Large cohort study finds interstitial lung disease independently increases lung cancer risk across all major subtypes, even ...

Public pigeon feeding in Hyderabad, though seen as kindness, can cause severe lung diseases. Experts warn that droppings and ...

Liquidia Q2 sales hit $8.84 million after Yutrepia launch; PH-ILD study shows stable tolerability and improved walking ...

YUTREPIA™ surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILDPositive interim data from ASCENT trial reinforces YUTREPIA’s ...

Pulmonary rehabilitation using minimal equipment achieved roughly the same benefits as when done with treadmills and other ...

The plaintiff is a neurosurgeon at the University of Virginia. He sued the University of Physicians Group alleging that a UVA ...

The FDA has granted accelerated approval to Hernexeos for the treatment of adults with unresectable or metastatic non-squamous NSCLC.

YUTREPIA surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILDPositive interim data from ASCENT trial reinforces YUTREPIA's tolerabil ...

Former Teva North America CEO Sven Dethlefs, PhD, to lead Celea PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated ...

Shares of Liquidia hit a six-year high after the company reported higher-than-expected initial demand for its hypertension treatment Yutrepia and surging revenue in the second quarter. The stock rose ...

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

Liquidia stock shot higher Tuesday after its new drug, Yutrepia, widely beat prescription and patient start expectations.